The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic (Q34554572)

3 August 2017

1 reference

title

The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic (English)

1 reference

3 August 2017

anti-retroviral agent

0 references

1 reference

1 reference

Mark Tyndall

5

0 references

Robert S Hogg

object named as

Robert Hogg

series ordinal

2

0 references

Julio Montaner

series ordinal

1

object named as

Julio S G Montaner

1 reference

3 August 2017

4

Thomas Kerr

1 reference

3 August 2017

3

Evan Wood

1 reference

3 August 2017

7

P Richard Harrigan

1 reference

3 August 2017

Adrian R Levy

6

1 reference

PubMed ID

16890841

3 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

3 August 2017

1 reference

3 August 2017

368

1 reference

3 August 2017

9534

1 reference

3 August 2017

531-536

1 reference

HIV in the United States at the turn of the century: an epidemic in transition

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Determinants of sexual risk-taking among young HIV-negative gay and bisexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Expanding access to HIV prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

The Global Fund to Fight AIDS, Tuberculosis and Malaria: funding for unpopular public-health programmes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

The search for effective HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Residual HIV-1 disease in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Rebound of plasma HIV viral load following prolonged suppression with combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Time to act: global apathy towards HIV/AIDS is a crime against humanity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Dimensions of the emerging orphan crisis in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Decline in deaths from AIDS due to new antiretrovirals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Community-based approaches to HIV treatment in resource-poor settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

HIV-1 and the aetiology of AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

The incidence rate of acquired immunodeficiency syndrome in selected populations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Antiviral effect of double and triple drug combinations amongst HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Effect of antiviral treatment on the shedding of HIV-1 in semen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

A tale of two futures: HIV and antiretroviral therapy in San Francisco.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Modelling the effect of combination antiretroviral treatments on HIV incidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

The direct costs of HIV/AIDS care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Is “3 by 5” enough? Recalculating the global need for antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

[Prevalence of antiretroviral drug resistance among previously untreated Spanish patients infected with HIV].

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

World Bank meeting concludes drug resistance should not prevent distribution of antiretroviral therapy to poor countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969162-9

7 January 2021

10.1016/S0140-6736(06)69162-9

Identifiers

DOI

1 reference

release_oxsoji7mandi3h7hnft6m5steq

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oxsoji7mandi3h7hnft6m5steq

24 November 2022

mapped directly with Wikidata item

PubMed ID

16890841

1 reference

PubMed ID

16890841